Akebia Therapeutics Inc. (NASDAQ: AKBA) announced that it has begun dosing participants in a Phase 1 clinical trial of AKB-9090 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE